重新考虑黑色素剂量:在睡眠障碍和并发症的老年患者中,高于正常水平的安全性和有效性
Stella M Valiensi1, Vanesa A Vera1, Agustín L Folgueira1
1Neurología-Medicina del Sueño, Hospital Italiano de Buenos Aires, Buenos Aires C1199ABB, Argentina.
Brain sciences
|October 29, 2025
概括
用于睡眠障碍的高剂量黑激素,在老年人中显示出显著的心血管和代谢益处. 这种细胞保护剂在高血压和糖尿病等疾病中得到改善,副作用最小.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 睡眠医学 睡眠医学
背景情况:
- 以睡眠调节而闻名的黑素也具有抗氧化,线粒体,免疫调节和抗炎性质.
- 这些细胞保护作用在比通常用于睡眠障碍的剂量更高的情况下被观察到.
- 黑素表现出良好的安全性概况,即使高剂量,副作用也很少,轻微且短暂.
研究的目的:
- 评估高剂量黑激素 (每天≥40毫克) 对患有睡眠障碍的老年患者心血管和代谢并发症的影响.
- 评估黑激素作为该群体中细胞保护剂的安全性和有效性.
主要方法:
- 追溯混合观察分析设计,结合队列分析和横截面研究.
- 81名患有睡眠障碍的老年患者 (平均年龄为74.4岁) 每天接受40-200毫克的黑激素,平均72.7毫克.
- 对照组包括81名年龄和性别匹配的睡眠障碍患者,未接受黑激素治疗.
主要成果:
- 在接受黑激素治疗的组中观察到动脉高血压,缺血性心脏病和糖尿病的显著降低.
- 临床实验室变量没有显著变化,除了酸酸酶水平较低的氨酸组.
- 在超过一半的患者中,长期治疗 (超过4年) 是常见的.
结论:
- 梅拉托尼的细胞保护剂量可能对老年人群的心血管和代谢健康产生有益影响.
- 黑色素显示出作为治疗剂的潜力,用于治疗睡眠障碍的老年患者的并发症.
- 这些发现支持进一步调查黑激素在老年人慢性疾病管理中的作用.
相关概念视频
01:19Management of Insomnia
523
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
523
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
502
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
502
01:15Drug Dosing: Geriatric Patients
219
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
219
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
183
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
183
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
227
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
227
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
223
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
223